The weight loss drug market just had its biggest shakeup since Ozempic went viral. A new high-dose Wegovy approved days ago, oral pills replacing injections, and federal pricing deals slashing costs by 75% — the landscape in March 2026 looks nothing like it did a year ago.
If you're trying to figure out which GLP-1 medication is right for you, here's everything you need to know.
The Four Drugs at a Glance
| Drug | Active Ingredient | Approved For | Max Dose | Avg. Weight Loss | Monthly Cost (TrumpRx) |
|---|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 Diabetes | 2.0 mg injection | 6–7% | $350 |
| Wegovy | Semaglutide | Obesity / CV Risk | 2.4 mg injection | ~15% | $350 |
| Wegovy HD | Semaglutide | Severe Obesity | 7.2 mg injection | 20.7% | $350 |
| Wegovy Pill | Semaglutide | Obesity | 25–50 mg oral | ~16.6% | $150 |
| Mounjaro | Tirzepatide | Type 2 Diabetes | 15.0 mg injection | ~15–20% | $350 |
| Zepbound | Tirzepatide | Obesity / Sleep Apnea | 15.0 mg injection | 21–22% | $350 |
How They Actually Work
These drugs fall into two camps based on their mechanism:
- Targets the GLP-1 receptor only
- Mimics one gut hormone
- Proven cardiovascular benefits (SELECT trial)
- Now available as a daily pill
- Manufactured by Novo Nordisk
- Targets both GLP-1 and GIP receptors
- Dual hormone action = stronger appetite suppression
- Superior weight loss in head-to-head studies
- Injection only (for now)
- Manufactured by Eli Lilly
The dual-action approach of tirzepatide is why Zepbound and Mounjaro consistently edge out semaglutide drugs on raw weight loss numbers. But the gap is shrinking — Wegovy HD's 20.7% result nearly matches Zepbound's 21–22%.
Weight Loss: The Numbers That Matter
Average percent body weight loss in clinical trials over 68–72 weeks.
The Price Revolution
A year ago, these drugs cost $1,000–$1,350 per month without insurance. The November 2025 pricing agreement between the Trump administration, Novo Nordisk, and Eli Lilly changed everything.
- **List price before deal:** $1,060–$1,350/month
- **TrumpRx cash price:** $350/month for injectables, $150/month for oral Wegovy
- **Medicare/Medicaid net price:** $245/month (fixed)
- **Medicare copay (starting July 2026):** Capped at $50/month
- **Where to buy:** TrumpRx.gov bypasses pharmacy benefit managers entirely
The oral Wegovy pill at $150/month is the most affordable branded GLP-1 option on the market. For patients who hate needles and want to save money, it's the obvious entry point.
Who Should Take What?
- **Choose Ozempic** if you have Type 2 diabetes and want blood sugar control (weight loss is secondary)
- **Choose Wegovy or Wegovy HD** if weight loss is the primary goal and you want proven heart benefits
- **Choose the Wegovy Pill** if you want convenience, lower cost, and can't tolerate injections
- **Choose Zepbound** if you want maximum weight loss and don't mind injections
- **Choose Mounjaro** if you have Type 2 diabetes and want the strongest dual-action drug
- **Ozempic** won't deliver dramatic weight loss — it's a diabetes drug first
- **Wegovy HD** is brand new with limited real-world data at the 7.2 mg dose
- **Wegovy Pill** shows slightly less weight loss than the injectable version
- **Zepbound** has no cardiovascular outcome trial data yet (unlike Wegovy)
- **Mounjaro** is not FDA-approved for weight loss — insurance may deny coverage
The Timeline: What Got Us Here
What's Coming Next
The current four-drug race is about to become a six-drug race. Two pipeline drugs could reshape the market again:
CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, an amylin analog. Early trials project approximately 23% weight loss — beating everything currently available. The FDA decision is expected by October 2026.
Retatrutide (Eli Lilly) is the so-called "Triple G" agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. Late-stage trial results show up to 28.7% body weight loss — a number that would blow away every drug on this list. Approval is anticipated in 2027.
Medicare Coverage: The $170 Billion Bet
Historically, Medicare couldn't cover weight loss drugs — the Medicare Modernization Act of 2003 explicitly excluded them. The 2026 policy shift treats obesity as a chronic metabolic disease, not a lifestyle choice.
The Medicare GLP-1 Bridge program launches July 1, 2026, offering direct access with $50 monthly copays. By January 2027, the permanent BALANCE Model will transition coverage into standard Part D plans.
Federal officials estimate this coverage expansion could save $170 billion over time by reducing downstream costs from heart failure, kidney disease, and other obesity-related conditions.
The Bottom Line
For maximum weight loss in 2026, Zepbound still holds the crown — but Wegovy HD is now within striking distance. For affordability and convenience, the oral Wegovy Pill at $150/month is a game-changer. And if you're on Medicare, mark your calendar for July 1.
The drugs are getting stronger, cheaper, and more accessible. The question is no longer whether GLP-1 medications work — it's which one fits your body, your budget, and your goals.
